Leishmania mexicana Infection of the Eyelid in a Traveler to Belize

Joseph M. Vinetz¹ and Lynn Soong²

¹Division of Infectious Diseases, Department of Medicine, University of California, San Diego School of Medicine, La Jolla, California; ²Departments of Microbiology & Immunology Pathology, University of Texas Medical Branch, Galveston, Texas, USA

A 50 year-old man, a United States resident, presented in Texas with a violaceous non-ulcerating lesion, involving the entire lower eyelid. The patient had traveled to a jungle area of Belize several hours drive from the capital city. Leishmania mexicana was isolated. The lesion only partially resolved after an initial course of sodium stibogluconate, requiring retreatment. At two years of follow-up, there was no relapse. The parasite isolated from the patient caused a progressive, non-ulcerating lesion in an experimental mouse footpad infection. This is an unusual case of cutaneous leishmaniasis in a traveler. Travelers must be educated about personal protective measures to prevent exotic infections acquired during travel.

Key Words: Leishmania mexicana, traveler, Belize.

Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites transmitted by the bite of phlebotomine sand flies. In the Americas, four distinct syndromes of leishmaniasis affect humans: cutaneous, mucocutaneous, diffuse cutaneous, diffuse cutaneous and visceral. In the American continent, visceral leishmaniasis is caused by Leishmania chagasi/infantum; this is an important emerging opportunistic disease in patients with AIDS [1]. Mucocutaneous leishmaniasis is also becoming common [2]. Involvement of the mucosa of the nose, mouth and pharynx as highly disfiguring complications of L. brazilienses usually occurs late after the cutaneous form appears. Of relevance to this case report, travelers returning from Belize [3-5], including British soldiers [6,7], have had a relatively high risk of L. brazilienses infection, which mandates parenteral treatment to forestall late mucocutaneous complications. In the United States, leishmaniasis has taken on increased clinical importance because natural infections have been found in dogs (foxhounds) in a number of states [8]. With the recent incursions of the U.S. armed forces into the Middle East, many military personnel have returned with Old World cutaneous leishmaniasis, with more than 500 confirmed parasitological clinical cases. Among American troops serving in Iraq, 653 cases of cutaneous and two cases of visceral leishmaniasis were reported by the end of March 2004. According to U.S. sources, the number of infected American soldiers may have been higher, from 750 to 1,250, or even more, which would include nearly 1% of U.S. troops serving in Iraq in 2003-2004 [9-12]. Therefore, it is of clinical significance when cases of cutaneous leishmaniasis present within the United States, especially in non-military personnel. Such infections most likely represent imported cases in travelers, but, given the autochthonous cases of canine leishmaniasis in the U.S., consideration must still be given to where patients acquired their infections.

Case report

A 50-year-old man traveled to a rural jungle area of Belize on vacation. He and his wife stayed seven days in a thatched-roof house and slept in hammocks without mosquito netting. Neither used insect repellent. One month after returning to his home on the Gulf coast of Texas, a non-ulcerated eye lesion developed (Figure 1). A biopsy was taken near the medial aspect of the lesion. A Giemsa-stained touch preparation of the biopsy showed intra- and extra-cellular amastigotes typical of Leishmania species (Figure 2). The biopsy specimen was cultured; parasites were visible seven days after the lesion was cultured. These parasites were identified as L. mexicana mexicana by isoenzyme testing at the United States Centers for Disease Control and Prevention, Atlanta, Georgia. Because of the reported prevalence of L. (Vianna) braziliensis in rural Belize, and because the lesion was progressive and in a cosmetically and functionally important anatomical area, the patient was given pentavalent antimony (sodium stibogluconate, Pentostam™) at a dose of 20 mg/Kg for 20 days. Only after treatment was completed was the infecting organism identified as L. m. mexicana. By the end of treatment, the lesion had more than 80% resolved. Two weeks after treatment was stopped, the lesion relapsed and continued to progress; Leishmania promastigotes again grew from an aspirate of the lesion. Antimony was restarted, continued for seven weeks, and the lesion resolved. Side effects from the first and second courses of antimonial treatment were primarily malaise and myalgia. Laboratory tests showed transient mild elevations in transaminases and serum lipase. An electrocardiogram showed mild flattening of the T waves. The patient was maintained on three additional months of oral itraconazole (200 mg/day). The patient’s lesion resolved completely and healed without scarring.

Discussion

We describe a case of New World cutaneous leishmaniasis involving the lower eyelid in a traveler to Belize. This case is
particularly notable because of the unusual location of the
infection, the relative refractoriness to treatment, and the
species of the Leishmania parasite, *L. m. mexicana*, which
caus[ed the lesion.]

New World cutaneous leishmaniasis typically presents as
enlarging papules that progress to ulcerative lesions; the lack of
ulceration in this case was atypical and led us to briefly
consider that this patient had become infected by
*Trypanosoma cruzi*, as manifested by Romana’s sign, since
*T. cruzi* is known to be endemic in Belize [13]. However, the
appearance of the biopsy on histopathologic examination was
not typical of Chagas disease, and the isolation of *Leishmania
m. mexicana* from the lesion confirmed the diagnosis.

Leishmaniasis affecting the eyelid has previously been reported
in both Old World and New World cutaneous leishmaniasis,
having been associated with *L. (Vianna) braziliensis* and *L.
major*, but without confirmation [14-17].

In Belize, the most feared form of Leishmaniasis is caused
by *L. (Vianna) braziliensis*, which is associated with
mucocutaneous complications and relative refractoriness to
therapy. Both cutaneous and mucocutaneous leishmaniasis
due to *L. (Vianna) braziliensis* and *L. m. mexicana* have been
observed as emerging health problems among travelers to
Belize and other places in Central America [4].

Pentavalent antimonial drugs remain the treatment of
choice for New World cutaneous and mucocutaneous
leishmaniasis [3-5,7], when the lesions are clinically judged
to require treatment. All cases of cutaneous leishmaniasis
caused by *L. (Vianna) braziliensis* must be treated. Many
cases of uncomplicated cutaneous leasions caused by *L. m.
mexicana* will self-resolve. Lesions on the face, the presence
of large or many lesions, or progressive, non-healing lesions
also necessitate treatment. Liposomal amphotericin B for *L.
(Vianna) braziliensis* has recently been reported to be
successful [18], but it is also associated with relapse [5].
Itraconazole was not found effective in primary treatment of
New world mucocutaneous leishmaniasis in a small
controlled clinical trial [19], although anecdotal evidence
suggests that this drug may have some utility in the treatment
of New World cutaneous leishmaniasis [20,21], particularly
in consolidation or maintenance therapy, as seen in our case.
Local, topical treatment with photodynamic therapy [22],
pomomomycin [23], and the immune stimulator imiquimod [24-26]
have also been shown to be effective treatments for *L.
(Vianna) braziliensis*-related New World cutaneous
leishmaniasis.

Our patient had a poor response to initial therapy. Two
factors could have contributed to this slow clinical cure. The
infecting strain of the parasite, *L. mexicana mexicana*, may
have had intrinsic refractoriness to treatment with sodium
stibogluconate. Since it is well known that the patient must
develop effective T cell immunity in order to cure a lesion,
whether spontaneously or in the presence of drug treatment,
our patient may have had some genetic basis for his relative
inability to form active delayed-type hypersensitivity. Precise
identification of infecting leishmanial parasites and their *in
vitro* drug susceptibility, if available in a timely way, would be
key for guiding therapy and indicating the risk of
mucocutaneous disease.

Given the recently-observed autochthonous transmission of
*Leishmania* infections among dogs in the United States
[8], we considered whether our patient acquired his infection
in Texas rather than during his travel to Belize. The patient
lives in suburban Houston, where there has not been any
observed cutaneous leishmaniasis. Given the travel history,
we believe that it is most likely that the patient acquired his
infection in the Belize jungle.

The patient’s clinical presentation was characterized by a
lack of ulceration and the finding of large numbers of intra-
and extra-cellular organisms. Cutaneous leishmaniasis is
 typified by its progression to ulceration over time, so the lack
of ulceration over several months of progressive infection is
striking. This clinical finding is consistent with the lack of
development of cell mediated immunity, which is necessary
for spontaneous self-cure in this syndrome.

Experimental inoculation of mouse footpads showed that
the *L. m. mexicana* isolate from the patient had a propensity
to induce ulcerative disease, even up to 10 weeks after
infection, in a well-established mouse model of cutaneous
leishmaniasis (Figure 3). The mouse model using this isolate
may be useful for determining mechanisms by which
*Leishmania* parasites induce ulceration in the protective T
cell responses. This patient’s isolated *Leishmania* was cultured
as axenic amastigotes in *vitro*, making detailed proteomic and
immunologic investigations of pathogenesis and protective
immunity feasible. Understanding such mechanisms may have
clinical utility in modifying sequel of scarring and may also
yield insight into how to appropriately use immunomodulators
in the management of cutaneous and mucocutaneous
leishmaniasis.

Acknowledgments

We thank Barbara Herwaldt, M.D. of the U.S. Centers for
Disease Control, Atlanta, Georgia, USA, the staff of the CDC
investigational drug service and the CDC Leishmania
diagnostic laboratory for their help in diagnosing and
managing this case. We also thank the nursing staff of the
University of Texas Medical Branch, Galveston, Texas, USA,
and the clinical house staff and fellows, particularly Bruno
Granwehr, M.D. and Miguel Montes-Walters of the Division
of Infectious Diseases at UTMB, who helped in the care of
the patient.

References

3. Marsden P.D. Mucosal Leishmaniasis (“espundia” Escomel, 1911),
and cutaneous leishmaniasis: an emerging health problem among
Figure 1. Patient with left lower eyelid progressive swelling, erythema, without ulceration. The puncture at the medial edge of the lesion is the biopsy site.

Figure 2. Giemsa-stained examination of a touch preparation of the patient’s lesion (400X). At left, mononuclear cells contain large clusters of *leishmania* amastigotes with scattered extracellular amastigotes visible. At right, many extracellular amastigotes are apparent, showing the poor T cell response to this infection. Kinetoplasts, extranuclear collections of minicircle DNA, are well-visualized in many parasites.

Figure 3. Appearance of the hind foot of a C57BL/6 mouse at 10 weeks after subcutaneous/intradermal inoculation of the patient’s Leishmania isolate. The lesion was progressive, non-healing, and had a remarkable absence of ulceration.